The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 16, 2024
Filed:
Jan. 19, 2021
Applicant:
Tsinghua University, Beijing, CN;
Inventors:
Assignee:
TSINGHUA UNIVERSITY, Beijing, CN;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 38/00 (2006.01); A61K 38/18 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); A61K 49/16 (2006.01); A61P 9/10 (2006.01); A61P 25/00 (2006.01); A61P 25/02 (2006.01); A61P 25/28 (2006.01); A61P 27/00 (2006.01); A61P 27/02 (2006.01); A61P 27/06 (2006.01); C07K 14/00 (2006.01); C07K 14/48 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C12P 21/08 (2006.01); G01N 33/53 (2006.01); A61K 9/00 (2006.01); A61K 38/17 (2006.01); A61L 27/38 (2006.01); A61P 21/00 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C12N 5/0793 (2010.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 38/185 (2013.01); A61P 9/10 (2018.01); A61P 25/00 (2018.01); A61P 25/02 (2018.01); A61P 25/28 (2018.01); A61P 27/00 (2018.01); A61P 27/02 (2018.01); A61P 27/06 (2018.01); C07K 14/48 (2013.01); C07K 16/00 (2013.01); C07K 16/2878 (2013.01); A61K 9/0048 (2013.01); A61K 38/1709 (2013.01); A61K 38/177 (2013.01); A61K 38/18 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61L 27/383 (2013.01); A61L 2300/414 (2013.01); A61P 21/00 (2018.01); A61P 25/14 (2018.01); A61P 25/16 (2018.01); C07K 14/47 (2013.01); C07K 14/705 (2013.01); C07K 14/70503 (2013.01); C07K 14/70578 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/35 (2013.01); C07K 2317/50 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/62 (2013.01); C07K 2317/622 (2013.01); C07K 2317/624 (2013.01); C07K 2317/626 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/31 (2013.01); C12N 5/0619 (2013.01); C12Y 207/10001 (2013.01); G01N 2333/46 (2013.01); G01N 2333/70575 (2013.01); G01N 2500/10 (2013.01);
Abstract
Provided is an isolated TrkB agonist antibody that binds to an epitope contained in one of the extracellular domains of TrkB and is capable of activating TrkB, wherein the extracellular domains comprises extracellular D1, D2, D3, D4, D5 domains and juxtamembrane domain of TrkB. Methods of using the TrkB agonist antibody in treating or reducing the risk of a TrkB associated conditions in a subject, wherein said condition is selected from cell differentiation, synaptic development, neural injury repairing and/or neurite branching.